CG
UTHR icon

Curat Global’s United Therapeutics UTHR Stock Holding History

Curat Global’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Hold
203
– – 0.09% 133
2026
Q1 		$120K Hold
203
– – 0.12% 117
2025
Q4 		$98.9K Hold
203
– – 0.11% 130
2025
Q3 		$85.1K Hold
203
– – 0.08% 151
2025
Q2 		$58.3K Hold
203
– – 0.06% 170
2025
Q1 		$62.6K Buy
+203
New +$69.6K 0.08% 169

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Curat Global's UTHR Position: Q2 2026 in Review

Curat Global held its United Therapeutics (UTHR) position steady in Q2 2026 at 203 shares worth $110K. The position accounts for 0.09% of the portfolio, ranked #133.

Curat Global first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. The position peaked at $120K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Curat Global held 203 shares of United Therapeutics worth $110K as of Q2 2026.
  • Curat Global left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.09% of Curat Global's portfolio in Q2 2026, its #133 holding.
  • Curat Global first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Curat Global's United Therapeutics position peaked at $120K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Curat Global's 13F filing for Q2 2026, filed 22 Jul 2026.